These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1918210)

  • 1. Use of third-generation cephalosporins. Anaerobes.
    Nichols RL; Smith JW
    Hosp Pract (Off Ed); 1991; 26 Suppl 4():11-7; discussion 48. PubMed ID: 1918210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Heel RC
    Drugs; 1985 Apr; 29(4):281-329. PubMed ID: 3888599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review.
    Jones RN
    Diagn Microbiol Infect Dis; 1995; 22(1-2):19-33. PubMed ID: 7587039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of intestinal anaerobes to new beta-lactam antibiotics.
    Bansal MB; Chuah SK; Thadepalli H
    Chemotherapy; 1984; 30(4):237-43. PubMed ID: 6744975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third generation cephalosporin antibiotics in surgical practice.
    Fry DE
    Am J Surg; 1986 Feb; 151(2):306-13. PubMed ID: 3511763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of cephalosporins with enhanced anti-anaerobic activity for treatment and prevention of anaerobic and mixed infections.
    DiPiro JT; May JR
    Clin Pharm; 1988 Apr; 7(4):285-302. PubMed ID: 3284692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative antimicrobial activity of aminothiazolyl methoxyimino cephalosporins against anaerobic bacteria, including 100 cefoxitin-resistant isolates.
    Jones RN; Barry AL; Aldridge KE; Gerlach EH
    Diagn Microbiol Infect Dis; 1987 Nov; 8(3):157-63. PubMed ID: 3501976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Barradell LB; Bryson HM
    Drugs; 1994 Mar; 47(3):471-505. PubMed ID: 7514976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefotaxime use in pediatric infections.
    Dajani AS
    Diagn Microbiol Infect Dis; 1995; 22(1-2):105-10. PubMed ID: 7587022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of ceftazidime and ceftriaxone.
    Keenholtz SL; Jacobus NV; Tally FP; Gorbach SL
    Clin Ther; 1983; 5(6):603-16. PubMed ID: 6313195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Third-generation cephalosporins.
    Klein NC; Cunha BA
    Med Clin North Am; 1995 Jul; 79(4):705-19. PubMed ID: 7791418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of cefotaxime in the treatment of surgical infections.
    Wittmann DH
    Diagn Microbiol Infect Dis; 1995; 22(1-2):173-82. PubMed ID: 7587036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the activity of third-generation cephalosporins against pneumonia-causing bacteria.
    Jones RN; Erwin ME; Bale M
    Diagn Microbiol Infect Dis; 1992 Jan; 15(1):73-80. PubMed ID: 1580897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in-vitro activity of cefodizime, cefpirome, carumonam and RU-28965 with other antimicrobials against anaerobes.
    Pascual A; Borobio V; Garcia-Iglesias MC; Perea EJ
    J Antimicrob Chemother; 1987 May; 19(5):701-3. PubMed ID: 3610904
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative activity of several beta-lactam antibiotics against anaerobes determined by two methods.
    Zabransky RJ; Birk RJ
    Clin Ther; 1987; 10(1):107-25. PubMed ID: 3450391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on the in vitro activity of ceftizoxime and other cephalosporin/cephamycin antimicrobial agents against clinically significant anaerobic bacteria.
    Aldridge KE
    Clin Ther; 1990; 12 Suppl C():3-12. PubMed ID: 2202509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiologic basis for the use of third-generation cephalosporins.
    Neu HC
    Am J Med; 1990 Apr; 88(4A):3S-11S. PubMed ID: 2183607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third-generation cephalosporins: a critical evaluation.
    Barriere SL; Flaherty JF
    Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newer cephalosporins: lessons to be learned from clinical trials in intraabdominal infections.
    Bumgardner GL; Simmons RL
    Am J Surg; 1988 May; 155(5A):5-10. PubMed ID: 3287968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in vitro activity of cefotaxime versus bacteria involved in selected infections of hospitalized patients outside of the intensive care unit.
    Doern GV
    Diagn Microbiol Infect Dis; 1995; 22(1-2):13-7. PubMed ID: 7587027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.